4^th International Conference on Wound Care,Wound Nursing, Tissue Repair & Regenerative Medicine October 5-6, 2018 Los Angeles, Southern California, USA

Biography:

Eugene Smit is an inventor, scientist, and entrepreneur. He received his PhD in polymer science from Stellenbosch University (South Africa) in 2008 with a focus on electrospinning and studies towards a high-throughput production of nanofiber yarns. He is the lead inventor on 32 granted nanofiber and electrospinning related patents and has several additional patents pending. He founded the Stellenbosch Nanofiber Company (SNC) in 2011 with the goal of commercializing the SNC BEST^TM high-throughput electrospinning technology.

Abstract:

The global market for advanced wound care is estimated to grow from US$ 10bn in 2017 to more than US$ 13bn by 2022. This rapid growth is driven by factors such as the global increase in the incidence of surgical wounds and various ulcer types (diabetic foot ulcers, pressure ulcers, and venous leg ulcers), the aging population, rising R&D activities in this field, and increasing awareness of the improvements in therapeutic outcomes and quality of life offered to patients by advanced wound care therapies. While the technical and commercial barriers to entry in the market of advanced wound care are high, electrospun fibers present a new category of materials that offer value addition that can be leveraged with existing products and can also be used to create new-to-the-world products. This potential has not fully been realized and there is huge capacity for electrospun fiber-based materials to be applied in developing novel dressings and devices aimed at controlling infection, managing wound moisture, and reducing scarring. This talk describes electrospun fiber developments and applications in advanced wound care and looks at commercialization aspects of electrospun fiber products. Some of the aspects covered will include: (a) Smart formulations and architectures that directly address the indication at the biointerface; (b) The use of a suitable high-throughput electrospinning platform technology; (c) The necessity for a good understanding of the regulatory path, economic and reimbursement factors; and (d) Clear understanding of the user needs from the design phase. All of these factors will affect the likelihood of successful transition of novel electrospun fiber based wound care product concepts from the lab to commercial production.

Biography:

Vita Boyar, an Assistant Professor of Pediatrics at Hofstra University Medical School, is a Board Certified Neonatologist and Certified Wound Specialist Physician, practicing both neonatology and wound care at Cohen Children’s Medical Center of NY, Northwell Health. She combines both specialties as a director of Neonatal Wound Services. Her neonatology research involves respiratory care and devices; it is closely intertwined with her work in Quality Improvement, specializing in pressure injury reduction. As a chair of Pressure Injury Prevention group at CCMC, she had implemented numerous protocols in Pressure Injury Prevention, achieving a reduction in medical-device related and ECMO related pressure injuries. Additional studies include treatments with natural products, point-of-care ultrasound in pediatric cutaneous wounds and skin integrity in preterm neonates. She serves as an advisor to Neonatal Israeli Society in their quest to implement Neonatal Skin Improvement Initiative and is a member of the International Society of Pediatric Wound Care.

Abstract:

Biography:

Benjamin Googe completed his undergraduate education at Johns Hopkins University where he received a BS in biomedical engineering focusing in cell and tissue engineering. He went on to attend medical school in his home state at the University of Mississippi Medical Center in Jackson, MS. He is continuing his training at UMMC and is currently a plastic surgery resident and engaged in a variety of plastic surgery research from wound care to facial aesthetics. He has 7 peer-reviewed publications, 11 presentations, and 2 patents in the field of medical device design.

Abstract:

Biography:

Abstract:

Introduction: Infection is generally the result of dynamic interactions between host, potential pathogen and the environment. It normally occurs when microorganisms manage to overcome the host's defence strategies, leading to harmful changes in the host. There are two particularly important terms we use when talking about infection. One is the pathogenicity, which refers to a microorganism's ability to cause disease. The other is virulence, which defines the degree of pathogenicity. Virulence is related to the properties of the microorganism that make it aggressive to the host (virulence factors) and to its ability to evade the host's defence mechanisms, e.g. the presence of a capsule that protects it from phagocytosis. A microorganism's pathogenicity is influenced not only by its virulence, but also by the host's ability to resist infection (defence mechanisms). Despite the fact that there are a large number of germs on skin's surface, all of them potentially pathogenic, they are usually harmless thanks to the effect of the skin's acid mantle. Moreover, under normal conditions the skin is an effective physical barrier against bacteria. As is well known, not all patients have the same risk of developing an infection when they have a wound. The factors that determine the risk of infection include the origin of the wound, the causal mechanism, age, and comorbidities present in the patient. There are various factors that favour the development of infection, which can be local (ischaemia, presence of necrotic tissue), general (malnutrition, diabetes, immunosuppressant therapy, etc.) or germdependent (e.g. virulence. INFECTION CONTINUUM The distinction between colonisation and infection is not entirely clear and in recent years great importance has been placed on the concept of bacterial load. Bacterial load means the concentration of germs per gram of tissue in the wound. It has been reported in the literature that a high bacterial load of around 105 colony forming units per gram of tissue can interfere with wound repair mechanisms and therefore prevent healing. This high bacterial load acts silently, showing no signs of infection. When the skin is broken, bacteria can cause contamination, colonisation and infection of the wound. We consider that a wound is contaminated when germs are temporarily present on the surface of the wound but do not proliferate, which does not affect correct healing of the wound. The term ‘colonisation’ is used to indicate that the germs in a wound proliferate and find a suitable environment in the ulcer in which to grow and multiply. There is another phase,) Critical colonisation   (Established microbial population, no healing progress, microbial imbalance, no signs of infection)Topical antimicrobial agents Infection (Microbial control) Systemic antibiotics and topical antimicrobial agent ©2002 ConvaTec Host resistance Microorganism Bowler PG. Ostomy Wound Management 2003; 49(1):44-53. 

Biography:

Mateusz Fijalkowski has completed his PhD in 2012 at Technical University of Liberec, Czech Republic. He is the head of the Metamaterial Laboratory. He is long involved in nanotechnology issues, in particular with synthesis of nanoparticles, surface modification and preparation of nanostructured films.

Abstract:

Gram-positive and gram-negative bacteria are currently considered to be a major health problem. Over the years, antibiotics have been used to suppress infections spread in both the public and the hospital environment. Advances in nanotechnology and the ability to synthesize metal oxide nanomaterials of a specific size and shape, will likely lead to the development of new antibacterial agents that will not require exclusive antibiotic treatment. Inorganic antibacterial reagents are very interesting group of materials that can be utilize in wound healing due to the possible replacement of antibiotics. Moreover, the process of wound healing can be accelerated using nanofibrous structures. The reason is that nanofibrous structures are very porous, with a small pore size that permeates the air to the skin and provides protection against the external environment.

The aim of our work was to prepare organic-inorganic structured composite materials which are characterized by high antimicrobial activity. For this purpose we selected medical grade poliurethane polymer from wchich we made a nanofibers mat. In the second step we graft zinc oxide nanoparticles by surface activation of nanofibers in vacuum plasma under argon atmosphere. For preparing stable ZnO nanoparticles colloid we use condencation process in etanolic solution. Antimicrobial properties were examine on gram-negative Escherichia Coli and gram-positive Staphylococcus Aureus bacteria.

Biography:

Dr. Roopa Manjunatha received her PhD degree from Indian Institute of Science, Bengaluru, in the area of Biomedical Instrumentation in 2014; she received M.E degree with the specialization in Instrumentation and Control from Birla Institute of Technology, Mesra, Ranchi in 2008. She worked as   a Post-doctoral fellow in the Centre of Biomedical Engineering, Indian Institute of Technology- Delhi. She is the co-founder of LifePhy Pvt. Ltd, a medtech start-up with a vision and mission of providing an technology support for Indian health care system. Her PhD work has been reported by media because of its novelty and usefulness. She has published many research articles in peer-reviewed journals and conference proceedings. She has been serving as a member of reviewer panel for reputed conference proceeding like IEEE-Sensors. Her research interests are mainly focused in the area of biomedical sensors, medical devices, transdermal drug delivery systems especially using iontophoresis & sonophoresis techniques.

Abstract:

Currently, the pharmaceutical research is focused on the development of improved drug delivery routes for the existing drugs. In this context, Transdermal Drug Delivery System (TDDS) has generated a lot of interest. In the last decade, 40% of the drug delivery candidates under clinical evaluation globally belonged to the transdermal category. Statistics reveal a market of $ 31.6 billion for TDDS products in the year 2015 and expected to increase up to $ 91.57 billion in the year 2025. One of the inherent advantages of TDDS is the ability to include the wide array of compounds- having either analgesic or anti-inflammatory actions—applied directly into the target area. TDDS have an edge over injectable and oral routes by enhancing patient compliance and bypassing the first-pass metabolism respectively. Iontophoresis (IOP) is one of the most popularly preferred TDDS, which uses electric potential to enhance the drug delivery through the biological membrane. In most of the clinical studies conducted using iontophoresis as well as commercially available iontophoresis system uses continuous Direct Current (DC) IOP for delivery of lidocaine Hydrochloride (HCL) on subjects. However continuous DC IOP had few side effects like electrical burns or erythema on the skin due to electrode polarization. Some studies suggested Alternating Current (AC) IOP is better than DC IOP to overcome electrode polarization. However, the driving force of AC IOP was less as compared to DC IOP to permeate lidocaine HCL drug across skin due to the presence of the negative cycle. Therefore, a current delivering technique has to optimized such as to minimize the electrode polarization and increase the driving force. In our present work, instead of using AC IOP, we have modulated a continuous DC by introducing an on-period (90 s) and off- period (30 s). During off-period, no drug ions will be pulled back as there will be no negative polarity in the modulated waveform. Also during off-period, the skin becomes depolarized and returns to its initial condition decreasing the chances of burning or erythema. Our experimental system successfully demonstrated that modulated IOP enhanced the lidocaine HCL permeation across the human skin at par with continuous DC IOP. Compared to the passive group, the flux of lidocaine HCl with an application of modulated and continuous IOP was about six-fold and ten-fold higher respectively. At 2.5% lidocaine HCL concentration, the time taken by modulated and continuous IOP to achieve therapeutic level was approximately 10 mins. At 5% lidocaine HCL, the therapeutic effect was achieved at approximately 5 min after applying iontophoresis waveform. This study suggests that modulated IOP with “on-off period” can be a promising alternative method that can be used in clinical settings apart from continuous DC IOP.

Biography:

Kaur A has completed her MBBS at the age of 24 years from Government Medical College And Hospital, Chandigarh (UT), INDIA. She is currently pursuing her post graduation junior residency i.e. MD dermatology, venereology, and leprosy from Government Medical College And Hospital, Chandigarh (UT), INDIA. She has 2 case reports that are under publications. She has presented around 5 posters and 2 oral presentations in different national conferences.

Abstract:

INTRODUCTION-Epidermolytic icthyosis (EI), formerly known as epidermolyic hyperkeratosis or bullous congenital ichthyosiform erythroderma is a rare genodermatosis inherited most commonly in an autosomal dominant fashion but may occur as a spontaneous mutation. It is classified under the non-syndromic icthyosis.

CASE- A 30 year old adult male patient presented with generalized involvement of the body with erythematous dry, hyperkeratotic plaques associated with diffuse scaling and short stature. It was associated with diffuse palmoplantar keratoderma. There were history of bullous lesions in childhood. He was born out of non-consanguineous marriage through normal vaginal delivery. Family and past history

was non significant. Testicular size were below the normal average and secondary sexual characters were absent.

INVESTIGATIONS- skin biopsy, hormonal profile, physical measurements were taken.

DIAGNOSIS- Epidermolyic Hyperkeratosis [PS(palms/soles involved)-2 type] with secondary hypogonadism and dwarfism.

CONCLUSION- Although epidermolytic hyperkeratosis is not associated with any underlying systemic abnormality, there are case reports with associated hypogonadism and may require early paediatric endocrinologist consultation for a better quality of life.

Biography:

Ankita Tuknayat is pursuing her post-graduate residency in Dermatology in Government Medical College and Hospital, Chandigarh, India. She has 2 international publications namely Cyclophosphamide Induced Hearing loss – Reversibility and Preventive strategies in  American Journal of Therapeutics and Extensive Donor Site Keloids in Follicular Unit Extraction Hair Transplantation in International Journal of Trichology. She has presented various papers as Speaker and multiple posters in various dermatology conferences across India. She has also won a second award in a poster presentation in a national conference on Dermatophytosis conducted in Post Graduate Institute of Medical Education and Research in 2017. She is an avid participant in various activities of Chandigarh Dermatology Society.

Abstract:

Biography:

My name is Akbar Mohammadrezaei. I was born in Urmia in 1986/03/29, in west Azerbaijan state of Iran. I am married with two children, one son and one daughter. I finished my primary educaton in 1981and secondary education in1985, both in Urmia. I was accepted in medicine department in Tabriz, in 1986. I graduated from medicine department in 1995. I did my military service as a doctor in army. I was afflicted by vitiligo for 14 years. The motivation behind this treatment was my own suffering. For years and years I did a lot of studies and then could cure myself in 5 months. I hope all people suffering from this disease will hear our voice and good news.

Abstract:

This article is about a skin disorder which manifests itself as white patches (pigment destruction) in different locations of the body. There are many classifications for this disorder such as segmented, focal, generalized and universal vitiligo. I have mentioned some of the current methods used in the treatment such as UV rooms but there are many risks and long term side effects to it.  Besides at the end of the treatment, the patient leaves the clinic without being treated with disappointment. I was suffering from the same disorder for 14 years so I can feel how deep is the depression and suffering of those vitiligo patients. My motivation behind the discovery of this treatment was me myself. I was suffering from the same disorder for 14 years. It was so painful to be out in the society where everybody gazes at you and some are even afraid to talk to you. Because of my economic issues, I did not have access to labs and research centesrs.  So I studied a lot and broadened my understanding and knowledge abut human body and biology. After I dicovered the treatment, I cured myself in 5months and then many more patients from England, Iran, Turkey and Azerbaijan. In my article, I have written about some blood tests the patients have to take first and mentioned the vitamins pills and the creams they should use( different for kids and adults). My only intention for writing this article is to let all my collegue dermatologists know about the new treatment. Moreover, the whole treatment takes 5 months or so and is affordable by everybody. If the patients follow the sımple advice mentioned in the article the disorder will not come back. I would kindly ask you to go through my article and read it deep. I have treated myself and many others, so I can replicate the treatment on the cases given by you. The treatment and progress is visiblr from the first month.